Astria Therapeutics, Inc.

NasdaqGM:ATXS 주식 보고서

시가총액: US$506.3m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Astria Therapeutics 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Jill Milne

최고 경영자

US$3.0m

총 보상

CEO 급여 비율20.4%
CEO 임기16yrs
CEO 소유권0.008%
경영진 평균 재임 기간4.3yrs
이사회 평균 재임 기간8.7yrs

최근 관리 업데이트

Recent updates

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10
Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

CEO 보상 분석

Jill Milne 의 보수는 Astria Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$82m

Dec 31 2023US$3mUS$602k

-US$73m

Sep 30 2023n/an/a

-US$55m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$2mUS$568k

-US$52m

Sep 30 2022n/an/a

-US$48m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$3mUS$536k

-US$219m

Sep 30 2021n/an/a

-US$219m

Jun 30 2021n/an/a

-US$222m

Mar 31 2021n/an/a

-US$199m

Dec 31 2020US$1mUS$520k

-US$37m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$1mUS$501k

-US$26m

Sep 30 2019n/an/a

-US$26m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$24m

Dec 31 2018US$1mUS$476k

-US$26m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$633kUS$462k

-US$27m

보상 대 시장: Jill 의 총 보상 ($USD 2.96M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Jill 의 보상이 증가했습니다.

CEO

Jill Milne (56 yo)

16yrs

테뉴어

US$2,955,504

보상

Ms. Jill C. Milne, PhD is a Co-founder of Astria Therapeutics, Inc. (formerly known as Catabasis Pharmaceuticals, Inc.), has been its Director, President and Chief Executive Officer since June 2008. She se...

리더십 팀

이름위치테뉴어보상소유권
Jill Milne
Co-Founder16yrsUS$2.96m0.0080%
$ 40.4k
Noah Clauser
CFO & Treasurer4.5yrsUS$1.35m0%
$ 0
Christopher Morabito
Chief Medical Officer1.9yrsUS$1.32m0%
$ 0
Benjamin Harshbarger
Chief Legal Officer4yrsUS$845.83k0%
$ 0
Keri McGrail
Senior Vice President of Human Resources3.2yrs데이터 없음데이터 없음
Andrea Matthews
Chief Business Officer6.8yrs데이터 없음데이터 없음
Andrew Komjathy
Chief Commercial Officer4.8yrs데이터 없음데이터 없음
John Ruesch
Senior Vice President of Pharmaceutical Sciences & Technical Operationsless than a year데이터 없음데이터 없음

4.3yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: ATXS 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Jill Milne
Co-Founder16yrsUS$2.96m0.0080%
$ 40.4k
Michael Kishbauch
Independent Director8.2yrsUS$157.67k0%
$ 0
Edward Scolnick
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Kenneth Bate
Independent Chairman of the Board10.4yrsUS$194.17k데이터 없음
Arthur Rubenstein
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Gregory Lapointe
Independent Director5.4yrsUS$163.67k0%
$ 0
Johannes Jacob Kastelein
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Michael Jirousek
Member of Scientific Advisory Board8.7yrsUS$700.79k데이터 없음
Jay Horton
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Roger Ulrich
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Eric Brass
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Sekar Kathiresan
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

8.7yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: ATXS 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.